72966-20-2

Usage

Chemical Properties

Yellow Solid

InChI:InChI=1/C16H14N2OS2/c19-16-17(11-13-7-3-1-4-8-13)15(20)18(21-16)12-14-9-5-2-6-10-14/h1-10H,11-12H2

Upstream product

• 622-78-6 Benzyl isothiocyanate 
• 624-83-9 methyl isocyanate 
• 55000-02-7 N-benzyl-S-chloroisothiocarbamoyl chloride 

Relevant academic research and scientific papers

Enzyme inhibitors

Compounds of general formula (I): where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disea

First non-ATP competitive glycogen synthase kinase 3 β (GSK-3β) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease

Glycogen synthase kinase 3 β (GSK-3β) has a central role in Alzheimer′s disease (AD). Selective inhibitors which avoid τ hyperphosphorylation may represent an effective therapeutical approach to the AD pharmacotherapy and other neurodegenerative disorders

Reaction of Glyoxal Di(tert-butylnitrone) with Benzyl Isothiocyanate

This reaction leads to the formation of three products: the expected compound 3, a 3-thioxo-1,2,4-thiadiazolidin-5-one 5, and the thiocarbamoylated derivative 10 of a substituted acetamidine derivative, which was indepently prepared from the postulated intermediates 6 and 9B.